云顶集团(中国)

Global
关于云顶集团(中国)

致力于纳米抗体创新药物研发

关于云顶集团(中国)
科研论文
截止现在，云顶集团(中国)生物研发团队在具有重要影响力的期刊上发表研究论文多篇。
2022-06-08
Nanobody-based label-free photoelectrochemical immunoassay for highly sensitive detection of SARS-CoV-2 spike protein
发表于:Analytica chimica acta. 2022 Jun 8;1211:339904
查看更多内容
2022-01-11
Preclinical evaluation of [99mTc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECTCT
发表于:European Journal of Nuclear Medicine and Molecular Imaging. 2022 May;49(6):1810-1821
查看更多内容
2021-01-31
A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential
发表于:MedComm (2020). 2021 Mar;2(1):101-113
查看更多内容
2020-10-16
Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
发表于:Journal for ImmunoTherapy of Cancer. 2020 Nov;8(2):e001156
查看更多内容
2020-10-15
A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade
发表于:Biochemical and Biophysical Research Communications. 2020 Oct 15;531(2):144-151
查看更多内容
2020-02-15
Evaluation of 64Cu radiolabeled anti-hPD-L1 Nb6 for positron emission tomography imaging in lung cancer tumor mice model
发表于:Bioorganic & Medicinal Chemistry Letters. 2020 Feb 15;30(4):126915
查看更多内容
总计 24 1234